Emergent BioSolutions | EBS - Cash And Equivalent


Emergent BioSolutions reported $111.7M in Cash and Equivalent for its fiscal quarter ending in December of 2023.





Cash And Equivalent Change Date
Acadia Pharmaceuticals USD 956.47M 105.02M Jun/2026
Akebia Therapeutics USD 162.64M 22.2M Mar/2026
ALKERMES USD 511.53M 159.98M Jun/2026
Alnylam Pharmaceuticals USD 1.71B 2.46M Jun/2026
Amarin USD 143.56M 12.5M Jun/2026
ANI Pharmaceuticals USD 311.18M 25.59M Mar/2026
BioMarin Pharmaceutical USD 2.22B 910.76M Mar/2026
Coherus Biosciences USD 88.88M 14.47M Dec/2025
Emergent BioSolutions USD 111.7M 23.9M Dec/2023
Exelixis USD 226.15M 256.34M Mar/2026
Glaxosmithkline GBP 3.44B 146M Mar/2026
Heron Therapeutics USD 26.12M 2.53M Mar/2026
Ionis Pharmaceuticals USD 350.06M 1.57B Jun/2026
Ironwood Pharmaceuticals USD 220.47M 5.01M Mar/2026
Lexicon Pharmaceuticals USD 38.09M 3.76M Mar/2026
Lonza CHF 719M 188M Dec/2025
Merck USD 5.33B 9.24B Mar/2026
Moderna USD 1.72B 185M Jun/2026
Myriad Genetics USD 115.2M 9.2M Jun/2026
Nektar Therapeutics USD 149.58M 134.46M Mar/2026
Neurocrine Biosciences USD 332.4M 65.9M Jun/2026
Pacira USD 205.88M 61.57M Jun/2026
Pfizer USD 976M 727M Jun/2026
PTC Therapeutics USD 1.05B 215.9M Jun/2026
Sanofi EUR 6.35B 806M Jun/2026
Sarepta Therapeutics USD 464.45M 336.83M Mar/2026
United Therapeutics USD 1.8B 523.5M Jun/2026
Vanda Pharmaceuticals USD 84.85M 14.83M Dec/2025